Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this case report, a novel Ayurvedic preparation of Catharanthus roseus, used alongside conventional chemotherapy, was associated with tumor stability and improved general health in a patient with advanced esophageal squamous cell carcinoma.

This article reviews the potential for low intensity ultrasound as an antidote for the peripheral cytotoxic side effects of taxane drugs in chemotherapy, presenting no new clinical results.

This study demonstrates that pH-responsive nanogels designed with comb-like anionic polymers significantly improved oral delivery of the chemotherapy drug camptothecin, enhancing drug stability in acidic conditions and release in the intestines, with increased cellular uptake and cytotoxic effects against colorectal carcinoma cells.

This study discusses various anti-cancer therapies, including chemotherapy and immunotherapy, emphasizing the challenges in classifying these medications due to their diverse chemical compositions, mechanisms of action, and effectiveness against different types of cancer.

In this study, XMU-MP-1 unexpectedly reduced cell proliferation and altered cell cycle progression in a model human hair follicle, possibly due to off-target kinase inhibition.

This review discusses various treatment challenges and toxicities in patients with relapsed follicular lymphoma and suggests that novel therapies could improve outcomes by reducing exposure to harmful chemotherapy cycles.

In this study, once-daily treatment with bimatoprost 0.03% solution significantly increased eyelash growth, thickness, and darkness in patients with chemotherapy-induced eyelash loss compared to placebo, and was well tolerated over one year.

This review examines dermatological side effects of taxane chemotherapy reported in past studies and highlights the necessity for identifying and managing these conditions to maintain cancer patients' quality of life; it presents no new clinical results.

This study found that permanent chemotherapy-induced alopecia was relatively common three years after treatment among breast cancer patients receiving adjuvant chemotherapy, particularly those on taxane-based regimens.

This review found that adding immune checkpoint inhibitors to cancer treatment regimens likely increases the incidence of specific drug-related skin toxicities in adult Asian patients, highlighting the need for careful monitoring and management strategies.

This review describes the variety of mucocutaneous side effects caused by antineoplastic chemotherapy, with emphasis on skin, nails, and mucous membranes, while highlighting potential severity and the possibility of needing to adjust or interrupt treatment in rare cases; it presents no new clinical results.

This article reviews trichoscopic signs of chemotherapy-induced alopecia, including exclamation marks, but reports no new clinical results.

In this study, researchers found that alkylating chemotherapy causes hair follicle stem cells to lose their regenerative ability by initially triggering proliferation followed by apoptosis, leading to permanent regeneration loss.

In this case report, a 64-year-old patient with chemotherapy-induced alopecia was treated with oral minoxidil and experienced good results, suggesting a potential new therapy for this challenging condition.

This letter discusses the urgent need for effective treatments for chemotherapy-induced alopecia and presents no new clinical findings.

Chemotherapy can cause skin side effects that affect patients' lives, but they can be managed to avoid interrupting cancer treatment.

This review discusses the cutaneous side effects of chemotherapy, noting that they frequently involve changes to skin, hair, and nails, and reports no new results.

This article explores the potential of combining biomarkers to assess and improve treatments for chemotherapy-induced alopecia, highlighting the limited availability of data on hair follicle damage markers with and without scalp cooling.

This case study reports that a woman with breast cancer experienced persistent alopecia after taxane chemotherapy and endocrine therapy, and significant improvement was seen with topical minoxidil.

This study found that in female breast cancer patients, supplementation with 400 mg IND02 (Cinnamon bark extract) thrice daily during chemotherapy significantly reduced severe weight loss and hair loss compared to placebo, with the treatment being well-tolerated and safe.

This study observed that 100% of cancer patients at Dr. Moewardi Surakarta Hospital receiving carboplatin-paclitaxel chemotherapy experienced grade 2 alopecia as an adverse drug reaction.

This study reported that chemotherapy-induced skin reactions in cancer patients are mostly mild to moderate and manageable with supportive care, suggesting that early dermatologic intervention can improve patient outcomes without interrupting chemotherapy.

In this review, researchers explored the complex mechanisms behind chemotherapy-induced side effects like nausea, fatigue, and hair loss, and discussed potential strategies using natural agents to manage these toxicities, improving understanding for targeted adjunct therapies.

This review discusses advances in protecting against chemotherapy-induced alopecia and reports no new clinical results; calcitriol and cyclosporine A emerged as promising agents in animal models with broader efficacy across multiple chemotherapy drugs.

In this study, scalp cooling therapy was found to be well tolerated and effective at improving hair preservation for Asian women with breast or gynecological cancers undergoing certain chemotherapy regimens, particularly weekly paclitaxel, compared to historical controls.

This review discusses the pathobiology of chemotherapy-induced alopecia and highlights challenges in managing it, reporting no new clinical results and emphasizing the need for well-designed preclinical models to develop effective treatments.

In a neonatal rat model, this study found that topical CDK2 inhibitors reduced chemotherapy-induced hair loss in 33 to 50% of the animals, suggesting a potential strategy for preventing alopecia in cancer patients.

This article discusses a unique case of permanent chemotherapy-induced alopecia in a patient receiving chemotherapy for breast cancer, characterized by a distinctive histologic finding and excludes bone marrow transplantation, but reports no new clinical results.

This study found that permanent alopecia can occur after certain chemotherapy treatments and presents as nonscarring hair loss similar to androgenetic alopecia, with specific histological features that could be misdiagnosed without proper clinicopathological correlation.

In this study, scalp hypothermia with the Theracool™ cooling machine was largely ineffective for preventing alopecia in breast cancer patients undergoing a chemotherapeutic regimen including cyclophosphamide and anthracyclines.